Monitor the S-4 registration statement and Personalis shareholder vote timeline. The floating exchange ratio creates TEM share price sensitivity at close; arbitrageurs will watch TEM's stock relative to the $46.00 floor. Integration and MRD reimbursement progress are key medium-term catalysts.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 20 $48.41entry
- T+1 · 4mo ago +1.18%α +0.34% · $48.98
- T+5 · 4mo ago −11.82%α −11.39% · $42.69
- T+20 · 3mo ago +6.67%α +2.55% · $51.64
- T+60 · 5w ago +40.92%α +36.08% · $68.22
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tempus AI (TEM) announced a definitive agreement to acquire Personalis (PSNL) for $16.25/share in a stock-for-stock transaction valued at $1.5B enterprise value (net of Tempus's existing stake). The deal brings Personalis's industry-leading MRD technology into Tempus's AI-enabled precision oncology platform, expanding into a $20B market opportunity. Closing is expected in late 2026/early 2027, subject to Personalis shareholder and regulatory approvals.
Key Financial Metrics
Key Facts
- Consideration of $16.25 per share, 6% premium to Friday's close and 28% premium to 30-day VWAP
- Total enterprise value of $1.5 billion, net of Tempus's existing ownership interest
- 100% stock transaction; Tempus may elect cash up to 50% of consideration, financed with cash on hand and credit facilities
- Floating exchange ratio capped at 0.3356 shares of TEM per PSNL share
- Personalis reported preliminary Q2 2026 revenue of $22.4 million and 10,384 clinical tests (33% QoQ test volume growth)
- Closing expected late 2026 or early 2027; subject to Personalis shareholder approval, regulatory approvals, and customary conditions
- Tempus has the right to terminate if TEM stock price falls below $46.00 before closing
Financial Impact
$1.5B enterprise value acquisition; Personalis Q2 revenue of $22.4M with 33% QoQ test volume growth. Tempus expects to fund cash portion from existing cash and credit facilities.
Risk Factors
- Personalis shareholder may not approve the merger
- Regulatory approvals could be delayed or impose conditions
- Integration risk combining two technology platforms
- Dilution to existing Tempus shareholders from stock consideration
- Tempus stock price could fall below $46.00, triggering Personalis termination right
- MRD market reimbursement may not develop as expected
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001193125-26-308472 |
| Document: 0001193125-26-308472-index-headers.html | 0001193125-26-308472 |
| Document: 0001193125-26-308472-index.html | 0001193125-26-308472 |
| Document: 0001193125-26-308472.txt | 0001193125-26-308472 |
Track record
45 reports on TEM
7 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +53.09% at T+60 after the Jul 30, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 9, 20267d ago Press Release Neutral 3/10 Entry $80.54 Now $64.76 −19.59% settles Feb 8
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $76.05 Now $64.76 −14.85% settles Feb 4
- Nov 4, 202612d ago Insider Cluster Neutral 3/10 Entry $70.43 Now $64.76 −8.05% settles Feb 3
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $77.80 Now $64.76 −16.76% settles Feb 1
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $78.48 Now $64.76 −17.48% settles Jan 29
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $77.84 Now $64.76 −16.80% settles Jan 27
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $76.61 Now $64.76 −15.47% settles Jan 26
- Oct 27, 202620d ago 144 Neutral 3/10 Entry $76.61 Now $64.76 −15.47% settles Jan 26
- Oct 23, 202624d ago 8-K Bullish 6/10 Entry $67.62 Now $64.76 −4.22% settles Jan 21
- Oct 22, 202626d ago EFFECT Neutral 4/10 Entry $63.81 Now $64.76 +1.49% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers